Head-to-Head Study Finds TheracosBio's BRENZAVVY® (bexagliflozin) Non-Inferior to Dapagliflozin in Chinese Patients With Type 2 Diabetes
TheracosBio Extends Partnership with Mark Cuban Cost Plus Drug Company
IPC Secures Distribution Rights to Independent Retail Pharmacies for BRENZAVVY
TheracosBio, IPC Announce Distribution Partnership to Make BRENZAVVY® (bexagliflozin) Available to Thousands of IPC Member Pharmacies
TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty
TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes
TheracosBio Announces Publication of Data on the Safety and Effectiveness of Brenzavvy™ (bexagliflozin) as an Adjunct to Metformin
TheracosBio Appoints Brian Connelly as Chief Executive Officer
After gaining its first FDA approval in its two-plus decades of existence, TheracosBio has made a CEO switch, replacing Al Collinson, Ph.D., with Brian Connelly.
As another SGLT2 diabetes drug hits the market, the obvious question is: How will it find a way to compete against formidable blockbusters Farxiga and Jardiance?